AMAG Pharmaceuticals — Q3 2011 Earnings Presentation
7 slides from AMAG Pharmaceuticals's earnings presentation, Nov 4, 2011
Slide 1: 3Q 2011 Commercial Results
3Q 2011 Commercial Results Total revenues for the third quarter were $17.6 million $15.6 million in net Feraheme product revenues Net Feraheme product revenues include a $3.0 million Medicaid reserve adjustment to reflect AMAG’s actual claims experience since launch Total Feraheme provider demand fo
Slide 2: Total Non-Dialysis IV Iron Market Decreased 15% in 3Q
Total Non-Dialysis IV Iron Market Decreased 15% in 3Q 3 -Results based on IMS Monthly Data.
Slide 3: Feraheme Provider Demand Increased Slightly in 3Q; Market Share Grew in All Segments
4 Feraheme Provider Demand Increased Slightly in 3Q Market Share Grew in All Segments -Results based on IMS Monthly Data. Feraheme Grams Market Share
Slide 4: Hematology Segment: 2.8%
Hematology Segment: Provider Demand Increased 2.8% 5 -Results based on IMS Monthly Data. Market Share
Slide 5: Hospital Decreased 7.5%
Hospital Segment: Provider Demand Decreased 7.5% 6 -Results based on IMS Monthly Data. Market Share
Slide 6: Nephrology Segment: 22%
Nephrology Segment: Provider Demand Increased 22% 7 -Results based on IMS Monthly Data. Market Share
Slide 7: Investor Relations Contact
Nasdaq: AMAG INVESTOR RELATIONS CONTACT: 617-498-3303 8